Top Global Pharmaceuticals & Biotech Growth Stocks

Top Global Pharmaceuticals & Biotech Growth Stocks

UPDATED Jul 03, 2022

What are the best Global Pharmaceuticals & Biotech Growth Stocks?

According to our Simply Wall St analysis these are the best Global Pharmaceuticals & Biotech growth companies. We look for companies with high forecasted growth and healthy balance sheets that can deliver sustained growth over the long term.

Our criteria to find Top Growth Companies

Growth

  • Companies with sustained revenue growth that outperforms the market are attractive to investors. These companies are most likely to appreciate in share price over time.

What do we look for?

  • Is the company forecast to have high earnings growth.

Healthy Balance Sheet

  • A healthy balance sheet is essential to drive growth opportunities and sustain the business.
  • Repayments on debt take precedence over other initiatives to improve shareholder returns, so investors want to make sure the company is comfortably positioned to cover its debts.

What do we look for?

  • Does the company have a manageable level of debt.
  • Is the company able to cover its interest repayments.

81 companies meet this criteria in the Global market

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CALTX is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 98.5% below our estimate of its fair value

  • Earnings are forecast to grow 60.26% per year

Risks

  • Shareholders have been diluted in the past year

  • Volatile share price over the past 3 months

View all Risks and Rewards

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CUV's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 30.4% below our estimate of its fair value

  • Earnings are forecast to grow 29.38% per year

  • Earnings grew by 15.2% over the past year

Risks

  • Significant insider selling over the past 3 months

View all Risks and Rewards

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CAMX is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 82.8% below our estimate of its fair value

  • Earnings are forecast to grow 52.56% per year

  • Earnings have grown 4.8% per year over the past 5 years

Risks

No risks detected for CAMX from our risks checks.

View all Risks and Rewards

Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: 603520's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Price-To-Earnings ratio (28.4x) is below the CN market (34.2x)

  • Earnings are forecast to grow 31.85% per year

  • Earnings grew by 31.7% over the past year

Risks

  • Has a high level of debt

View all Risks and Rewards

Anhui Anke Biotechnology (Group) Co., Ltd.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: 300009's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 68.6% below our estimate of its fair value

  • Earnings are forecast to grow 40.23% per year

Risks

  • Profit margins (11.5%) are lower than last year (21.5%)

  • Large one-off items impacting financial results

View all Risks and Rewards

Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: GENO's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 57.2% below our estimate of its fair value

  • Earnings are forecast to grow 55.56% per year

  • Earnings grew by 299.3% over the past year

Risks

No risks detected for GENO from our risks checks.

View all Risks and Rewards

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: ALVAL is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 96.8% below our estimate of its fair value

  • Earnings are forecast to grow 100.72% per year

Risks

  • Makes less than USD$1m in revenue (€298K)

  • Does not have a meaningful market cap (€59M)

View all Risks and Rewards

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: 603392's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 37.5% below our estimate of its fair value

  • Earnings are forecast to grow 26.7% per year

  • Earnings grew by 242% over the past year

Risks

  • High level of non-cash earnings

View all Risks and Rewards
Page 1 of 11